심방세동 치료를 위한 미국과 유럽의 심박수 및 율동 조절 약물요법 가이드라인 비교 연구

키워드

참고문헌 (66)

1. Gupta S, "Atrial fibrillation and mortality in critically ill patients: a retrospective study", Am J Crit Care, 24(4), pp.336~341 (2015)
2. Lee G, "Recognising and managing atrial fibrillation in the community", Br J Community Nurs, 19(9), pp.422~426 (2014)
3. Rahman F, "Global epidemiology of atrial fibrillation", Nat Rev Cardiol, 11(11), pp.639~654 (2014)
4. De Backer O, "Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update", Open Heart, 1(1), pp.e000020~ (2014)
5. Aryana A, "Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization", Heart Rhythm, 12(7), pp.1431~1437 (2015)
6. Zhirov IV, "Epidemiology and management of heart failure patients with atrial fibrillation", Kardiologiia, 55(3), pp.91~96 (2015)
7. Cutugno CL, "Atrial fibrillation: updated management guidelines and nursing implications", Am J Nurs, 115(5), pp.26~49 (2015)
8. Berry E, "Management of patients with atrial fibrillation:diagnosis and treatment", Nurs Stand, 26(22), pp.47~56 (2012)
9. Moukabary T, "Management of atrial fibrillation", Med Clin North Am, 99(4), pp.781~794 (2015)
10. Greenberg H, "Evidenced-based pharmacotherapy for rate control in atrial fibrillation", Crit Care Nurs Q, 36(2), pp.237~243 (2013)
11. Stead LG, "Evidence-based emergency medicine", systematic review abstract. Rhythm control with electrocardioversion for atrial fibrillation and flutter, 2009, pp.54(5), 745~747
12. Hargroves D, "Anticoagulants for stroke prevention in patients with atrial fibrillation", Br J Neurosci Nurs, (Supplement), pp.31~37 (2015)
13. Saltman AE, "Surgical approaches for atrial fibrillation", Cardiol Clin, 27(1), pp.179~188 (2009)
14. Chatterjee S, "Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis", Pacing Clin Electrophysiol, 36(1), pp.122~133 (2013)
15. Lafuente-Lafuente C, "Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation", Cochrane Database Syst Rev, 3 (2015)
16. Podrid PJ, "Aggravation of arrhythmia: a complication of antiarrhythmic drugs", J Cardiovasc Electrophysiol, 4(3), pp.311~319 (1993)
17. Chung R, "Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: impact on mortality", Pacing Clin Electrophysiol, 37(10), pp.1338~1348 (2014)
18. Frommeyer G, "Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms", Nat Rev Cardiol
19. Estrada JC, "Clinical use of and future perspectives on antiarrhythmic drugs", Eur J Clin Pharmacol, 64(12), pp.1139~1146 (2008)
20. Torres-Degayón, V, "Negative outcomes associated with medication in patients with chronic atrial fibrillation who present at the emergency department", J Clin Pharm Ther, 40(4), pp.452~460 (2015)
21. Freeman JV, "Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF)", Circ Cardiovasc Qual Outcomes, 8(4), pp.393~402 (2015)
22. Taylor CJ, "Rhythm control agents and adverse events in patients with atrial fibrillation", Int J Clin Pract, 64(8), pp.1069~1075 (2010)
23. Camm AJ, "What should we expect from the next generation of antiarrhythmic drugs?", J Cardiovasc Electrophysiol, 10(2), pp.307~320 (1999)
24. Lee EJ, "Evaluation of dronedarone as a therapeutic option for patients with atrial fibrillation", J Clin Pharm Ther, 39(2), pp.112~117 (2014)
25. Duray GZ, "Effects of dronedarone on clinical outcomes in patients with lone atrial fibrillation: pooled post hoc analysis from the ATHENA", EURIDIS, J Cardiovasc Electrophysiol, pp.2011, 22(7)[DOI]
26. Rosman J, "Possible proarrhythmia with dronedarone", J Cardiovasc Electrophysiol, 24(1), pp.103~104 (2013)
27. Allen Lapointe NM, "Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation", Am Heart J, 166(5), pp.871~878 (2013)
28. Musco S, "Drug therapy for atrial fibrillation", Med Clin North Am, 92(1), pp.121~141 (2008)
29. Capucci A, "Clinical pharmacology of antiarrhythmic drugs", Drugs Aging, 13(1), pp.51~70 (1998)
30. Craig T, "2-13 AHA", ACC, J Am Coll Cardiol, pp.2014, 64[DOI]
31. Camm AJ, "Guidelines for the management of atrial fibrillation", Eur Heart J, 31, pp.2369~2429 (2010)
32. Camm AJ, "2012 focused update of the ESC guidelines for the management of atrial fibrillation", Eur Heart J, 33, pp.2719~2747 (2012)
33. Estes NA III, "ACC", AHA, Circulation, pp.2008, 117[DOI]
34. Nieuwlaat, R, "Lenient rate control is as effective as strict rate control for preventing cardiovascular events in AF", ACP J Club, 153(2), pp.JC2~4 (2010)
35. Kowey PR, "Physician stated atrial fibrillation management in light of treatment guidelines: data from an international, observational prospective survey", Clin Cardiol, 33(3), pp.172~178 (2010)
36. Curtis AB, "Update on the clinical management of atrial fibrillation:guidelines and beyond", Postgrad Med, 123(6), pp.7~20 (2011)
37. Rajagopalan B, "Management of atrial fibrillation: what is new in the 2014 ACC", AHA, Postgrad Med, pp.2015, 127(4)[DOI]
38. Phillips SE, "Guideline-specific management of atrial fibrillation", Formulary, 45(5), pp.156~164 (2010)
39. Ariansen I, "Guidelines' criteria for rate control in atrial fibrillation: are they useful?", Scand Cardiovasc J, 44(3), pp.132~138 (2010)
40. Dixon BJ, "Principal atrial fibrillation discharges by the new ACC", AHA, Arch Intern Med, pp.2005, 165(16)[DOI]
41. Kirchhof P, "Management of atrial fibrillation in seven European countries after the publication of the 2010ESC guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF)", Europace, 16(1), pp.6~14 (2014)
42. Savelieva I, "Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC guidelines", Europace, 16(2), pp.162~173 (2014)
43. Kirchhof P, "Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology", European Heart Rhythm Association, American Heart Association, pp.Heart Rhythm Society, and the Canadian Cardiovascular Society, Eur Heart J[DOI]
44. Chen S, "Vernakalant as a novel anti-arrhythmic agent for converting of atrial fibrillation, molecular mechanism, updated clinical efficacy, and future development", Curr Pharm Des
45. Conde D, "Vernakalant for the conversion of atrial fibrillation:the new kid on the block?", Ann Noninvasive Electrocardiol, 19(4), pp.299~302 (2014)
46. Rudiger A, "Suitability, efficacy, and safety of vernakalant for new onset atrial fibrillation in critically ill patients", Crit Care Res Pract
47. Camm AJ, "The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A?", Curr Cardiol Rev, 10(4), pp.309~314 (2014)
48. Duggan ST, "Intravenous vernakalant: a review of its use in the management of recent-onset atrial ribrillation", Drugs, 71(2), pp.237~252 (2011)
49. Ehrlich JR, "Novel approaches for pharmacological management of atrial fibrillation", Drugs, 69(7), pp.757~774 (2009)
50. Mao ZL, "Population Pharmacokinetics of Vernakalant Hydrochloride Injection (RSD1235) in Patients With Atrial Fibrillation or Atrial Flutter", J Clin Pharmacol, 52(7), pp.1042~1053 (2012)
51. Torp-Pedersen C, "Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study", Europace, 13(8), pp.1118~1126 (2011)
52. Singh BN, "Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter", N Engl J Med, 357(10), pp.987~999 (2007)
53. Rosa GM, "Pharmacokinetic and pharmacodynamic profile of dronedarone, a new antiarrhythmic agent for the treatment of atrial fibrillation", Expert Opin Drug Metab Toxicol, 10(12), pp.1751~1764 (2014)
54. Iannone P, "Dronedarone for atrial fibrillation:the limited reliability of clinical practice guidelines", JAMA Intern Med, 174(4), pp.625~629 (2014)
55. for at Least 6 mOnths for the Maintenance of Sinus Rhythm in Patients with AF, "J Cardiovasc Electrophysiol", 2010, 597~605
56. Lee EJ, "Evaluation of dronedarone as a therapeutic option for patients with atrial fibrillation", J Clin Pharm Ther, 39(2), pp.112~117 (2014)
57. Turgeon J, "Effects of drug metabolism, metabolites, and stereoselectivity on antiarrhythmic drug action", J Cardiovasc Electrophysiol, 1(3), pp.238~260 (1990)
58. Lin CY, "Factors predisposing to ventricular proarrhythmia during antiarrhythmic drug therapy for atrial fibrillation in patients with structurally normal heart", Heart Rhythm, 12(7), pp.1490~1500 (2015)
59. CalÒ L, "Upstream effect for atrial fibrillation: still a dilemma?", Pacing Clin Electrophysiol, 34(1), pp.111~128 (2011)
60. Kumagai K, "Upstream therapy for atrial fibrillation", Nihon Rinsho, 71(1), pp.86~90 (2013)
61. Goette A, "Hammwöhner M, Bukowska A. Upstream therapy for atrial fibrillation", Herzschrittmacherther Elektrophysiol, 25(1), pp.33~40 (2014)
62. Danelich IM, "Clinical update on the management of atrial fibrillation", Pharmacotherapy, 33(4), pp.422~446 (2013)
63. Pandya B, "An avoidable antiarrhythmic side effect", Br J Hosp Med (Lond), 67(1), pp.M14~M15 (2006)
64. Shu J, "Pharmacotherapy of cardiac arrhythmiasbasic science for clinicians", Pacing Clin Electrophysiol, 32(11), pp.1454~1465 (2009)
65. Heijman J, "New directions in antiarrhythmic drug therapy for atrial fibrillation", Future Cardiol, 9(1), pp.71~88 (2013)
66. Darbar D, "Future of antiarrhythmic drugs", Curr Opin Cardiol, 21(4), pp.361~337 (2006)

관련 논문AI추천